| Product NDC: | 52544-287 |
| Proprietary Name: | Levonorgestrel |
| Non Proprietary Name: | Next Choice One Dose |
| Active Ingredient(s): | 1.5 mg/1 & nbsp; Next Choice One Dose |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 52544-287 |
| Labeler Name: | Watson Pharma, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA200670 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20120716 |
| Package NDC: | 52544-287-54 |
| Package Description: | 1 BLISTER PACK in 1 CARTON (52544-287-54) > 1 TABLET in 1 BLISTER PACK |
| NDC Code | 52544-287-54 |
| Proprietary Name | Levonorgestrel |
| Package Description | 1 BLISTER PACK in 1 CARTON (52544-287-54) > 1 TABLET in 1 BLISTER PACK |
| Product NDC | 52544-287 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Next Choice One Dose |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20120716 |
| Marketing Category Name | ANDA |
| Labeler Name | Watson Pharma, Inc. |
| Substance Name | LEVONORGESTREL |
| Strength Number | 1.5 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Inhibit Ovum Fertilization [PE],Progesterone Congeners [Chemical/Ingredient],Progesterone Congeners [Chemical/Ingredient],Progestin [EPC],Progestin-containing Intrauterine Device [EPC] |